Efficacy of Tiotropium Inhalation Powder in African-American Patients with Chronic Obstructive Pulmonary Disease

REFERENCES

• NHLBI Working Group. Respiratory diseases disproportionately affecting minorities. Chest 1995; 108: 1380–1392, [published erratum appears in Chest 1996; 109:295]
   PubMed Web of Science ®Google Scholar
• Mannino D M, Reichert M M, Davis K J. Lung function decline and outcomes in an adult population. AmJ Respir Crit Care Med 2006; 173: 985–990
   PubMed Web of Science ®Google Scholar
• Chatila W M, Hoffman E A, Gaughan J, Robinswood G B, Criner G J, for the National Emphysema Treatment Trial Research Group. Advanced emphysema in African American and white patients: Do differences exist?. Chest 2006; 130: 108–118
   PubMed Web of Science ®Google Scholar
• Chatila W M, Wynkoop W A, Vance G, Criner G J. Smoking patterns in African Americans and whites with advanced COPD. Chest 2004; 125: 15–21
   PubMed Web of Science ®Google Scholar
• Dransfield M T, Davis J J, Gerald L B, Bailey W C. Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. Resp Med 2006; 100: 1110–1116
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. Chronic Obstructive Pulmonary Disease Data Fact Sheet. U.S. Department of Health and Human Services, http://www.nhlbi.nih.gov/health/public/lung/other/copd_fact.htm March 2003. Available from. Accessed August 14, 2006
   Google Scholar
• Nelson H S, Weiss S T, Bleeker E R, Yancey S W, Dorinsky P M, the SMART Study Group. The salmeterol multicenter asthma research trial, a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 126: 15–26
   Google Scholar
• Kalus J S, Nappi J M. Role of race in the pharmacotherapy of heart failure. Ann Pharmacother 2002; 36: 471–478
   PubMed Web of Science ®Google Scholar
• Exner D V, Dries D L, Domanski M J, Cohn J N. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N EnglJ Med 2001; 344: 1351–1357
   PubMed Web of Science ®Google Scholar
• Carson P, Ziesche S, Johnson G, Cohn J N, for the Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vaso-dilator-heart failure trials. J Card Fail 1999; 5: 178–187
   PubMedGoogle Scholar
• Disse B, Speck G A, Rominger K L, Witek T J, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64: 457–464
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler D A, Jones P W, Wanner A, San Pedro G, ZuWallack R L, Menjoge S S, Serby C W, Witek T J. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur RespirJ 2002; 19: 217–224
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord J A, Greefhorst A P, Bantje T A, Kesten S, Koducki L, Cornelissen P JG. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur RespirJ 2002; 19: 209–216
   PubMed Web of Science ®Google Scholar
• Celli B, Zu Wallack R, Wang S, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Ann Intern Med 2005; 143: 317–326
   PubMed Web of Science ®Google Scholar
• Niewoehner D, Rice K, Cote C, Korducki L, Cassino C, Kesten S. Characteristics of COPD and response to once-daily tiotropium in African Americans in the VA medical system. Proc American Thorac Soc 2005; 2: A543
   Google Scholar
• Agency-wide Race and Ethnicity Working Group from the U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, Office of the Commissioner. Guidance for industry: collection of race and ethnicity data in clinical trials (Draft guidance, January 2003). U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, Office of the Commissioner. Rockville, MD, 2003
   Google Scholar
• Morris J F, Koski A, Temple W P, Claremont A, Thomas D R. Fifteen year interval spirometric evaluation of the Oregon predictive equations. Chest 1988; 93: 123–127
   PubMed Web of Science ®Google Scholar
• Hankinson J L, Odencrantz J R, Fedan K B. Spirometric reference values from a sample of the general US population. AmJ Respir Crit Care Med 1999; 159: 179–187
   PubMed Web of Science ®Google Scholar
• Bestall J C, Paul E A, Garrod R, Garnham R, Jones P W, Wedzicha J A. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581–586
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Standardization of spirometry – 1994 update: statement of the American Thoracic Society. Am J Respir Crit Care Med 1995; 152: S77–S120
   PubMed Web of Science ®Google Scholar
• Eakin E G, Resnikoff P M, Prewitt L M, Ries A L, Kaplan R M. Validation of a new dyspnea measure: The UCSD Shortness of Breath Questionnaire, University of California, San Diego. Chest 1998; 113: 619–624
   PubMed Web of Science ®Google Scholar
• Evelyn B, Toigo T, Banks D, Pohl D, Gray K, Robins B, Ernat J. Participation of racial/ethnic groups in clinical trials and race-related labeling: A review of new molecular entities approved 1995–1999. US Food and Drug Administration, Rockville, MD 2001, http://www.fda.gov/cder/reports/race_ethnicity/race_ethnicity_report.htm Available at. Accessed August 15, 2006
   Google Scholar
• Israel E, Drazen J M, Liggett S B, Boushey H A, Cherniack R M, Chinchilli V M, Cooper D M, Fahy J V, Fish J E, Ford J G, Kraft M, Kunselman S, Lazarus S C, Lemanske R F, Jr, Martin R J, McLean D, Peters S P, Silverman E K, Sorkness C A, Szefler S J, Weiss S T, Yandava C N, for the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. The effect of polymorphisms of the β2-adrenergic receptor on the response to regular use of albuterol in asthma. AmJ Respir Crit Care Med 2000; 162: 75–80
   PubMed Web of Science ®Google Scholar
• Israel E, Chinchilli V M, Ford J G, Boushey H A, Cherniack R, Craig T J, Deykin A, Fagan J K, Fahy J V, Fish J, Kraft M, Kunselman S J, Lazarus S C, Lemanske R F, Jr, Liggett S B, Martin R J, Mitra N, Peters S P, Silverman E, Sorkness C A, Szefler S J, Wechsler M E, Weiss S T, Drazen J M, for the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled, cross-over trial. Lancet 2004; 364: 1505–1512
   PubMed Web of Science ®Google Scholar
• Lima J J, Thomason D B, Mohamed M HN, Eberle L V, Self T H, Johnson J A. Impact of genetic polymorphisms of the β2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999; 65: 519–525
   PubMed Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404
   PubMed Web of Science ®Google Scholar
• National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume–reduction surgery with medical therapy for severe emphysema. N EnglJ Med 2003; 348: 2059–2073
   PubMed Web of Science ®Google Scholar
• Dusser D, Bravo M L, Iacono P, on behalf of the Mistral study group. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur RespirJ 2006; 27: 547–555
   PubMed Web of Science ®Google Scholar
• Johnson J A, Burlew B S, Siles R N. Racial differences in β -adrenoreceptor-mediated responsiveness. J Cardiovasc Pharmacol 1995; 25: 90–96
   PubMed Web of Science ®Google Scholar
• Rutledge D R, Wallace A, Steinberg J D, Cardozo L, Lavine S J. Racial differences in drug response: isoproterenol effects before and after propranolol. Pharm Res 1991; 8: 754–757
   PubMed Web of Science ®Google Scholar